ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Low-Dose IFN Not Effective Against Melanoma, Study Finds

December 26, 2003

In Phase II Study, Vaccine IMA910 Stimulated Immune Response

February 24, 2012

BSA Approves 3 Concepts For Grants Worth $44 Million.

November 30, 2001

Seer Gets Extra $5000,000 to Permit Addition Of One Registry To Braden Coverage Of Blacks, Hispanics

October 22, 1982

NCI-Approved Clinical Trials Listed For April 2001

May 25, 2001

In Brief: Harvard’s Richmond Said To Be The Choice As Asst. secretary; Lee Clark Convalescing

May 6, 1977